Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Leukemia

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Leuk Lymphoma

Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE

doi: 10.1080/10428194.2025.2495369

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

ELCC 2026

Lung, Respiratory and Thoracic Cancer

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

Gastrointestinal Cancer

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial

Ann Oncol

Blay JY, Devin Q, Toulmonde M, Dufresne A, Penel N, Adenis A, Rios M, Bertucci F, Duffaud F, Firmin N, Valentin T, Bompas E, Collard O, Pracht M, Hervieu A, Verret B, Ray-Coquard I, Cassier P, Henon C, Perol D, Italiano A, Chabaud S, Le Cesne A

doi: 10.1016/j.annonc.2025.05.535

Breast Cancer

Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records

Lancet Oncol

Hassan H, Allen I, Rahman T, Allen S, Knott C, Huntley C, Loong L, Garrett A, Walburga Y, Morris E, Hardy S, Torr B, McRonald F, Vernon S, Lüchtenborg M, Pethick J, Santaniello F, Goel S, Eccles DM, Turnbull C, Tischkowitz M, Pharoah P, Antoniou AC

doi: 10.1016/S1470-2045(25)00156-1

Leukemia

Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study

Br J Haematol

Breccia M, Giai V, Rosso T, Pregno P, Castagnetti F, Bonifacio M, Capodanno I, Tiribelli M, Stagno F, Mulas O, Gozzini A, Patriarca A, Sorà F, Loglisci G, Rossi AR, Coppi MR, Miggiano MC, Di Raimondo F, Rosti G, Pane F, Saglio G, Ciccone G, Specchia G

doi: 10.1111/bjh.70332

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Related content

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial

Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records

Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study